<DOC>
	<DOC>NCT02046616</DOC>
	<brief_summary>This open-label, single-arm study will evaluate the safety, efficacy, and tolerability of subcutaneously administered RoActemra/Actemra (tocilizumab) in monotherapy or in combination with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who are na√Øve to RoActemra/Actemra. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 24 weeks.</brief_summary>
	<brief_title>A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Active rheumatoid arthritis (RA) according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria Moderate to severe RA with a DAS28ESR &gt; 3.2 Inadequate response and/or intolerance to MTX or other nonbiologic DMARDs and/or where MTX or other nonbiologic DMARDs are inappropriate Oral corticosteroids (&lt;/= 10 mg/day prednisolone or equivalent) and nonsteroidal antiinflammatory drugs (NSAIDs) are permitted if on stable dose regimen for &gt;/= 4 weeks prior to baseline Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline Receiving treatment on an outpatient basis, not including RoActemra/Actemra Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline Rheumatic autoimmune disease other than RA Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 Prior history of or current inflammatory joint disease other than RA Exposure to RoActemra/Actemra or any other biologic DMARDs at any time prior to baseline Treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational drug, whichever is longer) of screening Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies Evidence of serious concomitant disease or disorder Known active current or history of recurrent infection Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening Active TB requiring treatment within the previous 3 years Positive for hepatitis B or hepatitis C Primary or secondary immunodeficiency (history of or currently active) Pregnant or lactating women Neuropathies or other conditions that might interfere with pain evaluation Inadequate hematologic, renal or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>